| Latest Acadia Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 06/05/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development
SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of Roger G. Mills, M.D., as Executive... More...>> |
| 05/15/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Added to NASDAQ Biotech Index
SAN DIEGO, May 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it was selected for addition to the NASDAQ... More...>> |
| 05/10/2006 | 4:01PM | PRNUS | ACADIA Pharmaceuticals Reports First Quarter 2006 Financial Results
SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter... More...>> |
| 05/08/2006 | 4:06PM | PRNUS | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:... More...>> |
| 05/03/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 10, 2006
ACADIA to Host Conference Call and Webcast on Wednesday, May 10, 2006, at 5:00 p.m. Eastern Time
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central... More...>> |
| 04/27/2006 | 11:26PM | PRNUS | ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced today the pricing of its public offering of 4,947,229 shares of its common stock. The public offering price of $12.00 per share resulted in gross proceeds of $59.4 million and net proceeds, after underwriting commissions... More...>> |
| 04/24/2006 | 6:15AM | PRNUS | ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced today the filing of a preliminary prospectus supplement to its effective shelf registration statement previously filed with the Securities and Exchange Commission relating to a proposed underwritten public offering of $75... More...>> |
| 04/19/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Announces Positive Clinical Trial Results Demonstrating That ACP-103 Increases Slow Wave Sleep
SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today reported top-line results from a proof-of-concept clinical study that assessed the effect of ACP-103 on deep, or slow wave, sleep in healthy older volunteers using polysomnography (PSG). Results of the study demonstrated that... More...>> |
| 03/23/2006 | 4:01PM | PRNUS | ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients Wi
Conference Call Scheduled for Today, March 23, 2006 at 5:00 p.m. Eastern Time
SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today reported results from its Phase II clinical trial of ACP-103 in patients with Parkinson's disease suffering from treatment-induced psychosis. ACP-103... More...>> |
| 03/02/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor... More...>> |
| 03/01/2006 | 4:01PM | PRNUS | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2005
SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the fourth quarter... More...>> |
| 02/22/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2005 Results on March 1, 2006
ACADIA to Host Conference Call and Webcast on Wednesday, March 1, 2006, at 5:00 p.m. Eastern Time
SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for... More...>> |
| 02/07/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference 2006 on February 14, 2006
SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Uli Hacksell, Ph.D., Chief Executive Officer... More...>> |
| 01/17/2006 | 7:00AM | PRNUS | ACADIA Pharmaceuticals Announces Additional $10 Million Equity Investment by Sepracor
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced that Sepracor Inc. (NASDAQ:SEPR) has completed... More...>> |
| 01/09/2006 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs
SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced the appointment of David C. Furlano, Ph.D... More...>> |
| 12/15/2005 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Discovers Novel Isoform-Selective Retinoic Acid Receptor Agonists
SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced publication of research, in both the Journal of... More...>> |
| 12/01/2005 | 9:00AM | PRNUS | ACADIA Pharmaceuticals Reports Results From Phase II Study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathis
SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported results from a Phase II study that showed that ACP-103... More...>> |
| 11/10/2005 | 4:02PM | PRNUS | Acadia Pharmaceuticals Reports Third Quarter 2005 Financial Results
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter... More...>> |
| 11/10/2005 | 4:01PM | PRNUS | ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced initial results from an ongoing clinical trial... More...>> |
| 11/03/2005 | 9:01AM | PRNUS | ACADIA Pharmaceuticals to Announce Third Quarter 2005 Financial Results on November 10, 2005
ACADIA to Host Conference Call and Webcast on Thursday, November 10, 2005, at 5:00 p.m. Eastern Time
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for... More...>> |